 Connection
Cynthia Firnhaber to Cost-Benefit Analysis
This is a "connection" page, showing publications Cynthia Firnhaber has written about Cost-Benefit Analysis.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.672 |
|
|
|
-
Schnippel K, Michelow P, Chibwesha CJ, Makura C, Lince-Deroche N, Goeieman B, Mulongo M, Jordaan S, Firnhaber C. Cost-effectiveness of using the Cervex-Brush (broom) compared to the elongated spatula for collection of conventional cervical cytology samples within a high-burden HIV setting: a model-based analysis. BMC Health Serv Res. 2015 Nov 06; 15:499.
Score: 0.440
-
Campos NG, Lince-Deroche N, Chibwesha CJ, Firnhaber C, Smith JS, Michelow P, Meyer-Rath G, Jamieson L, Jordaan S, Sharma M, Regan C, Sy S, Liu G, Tsu V, Jeronimo J, Kim JJ. Cost-Effectiveness of Cervical Cancer Screening in Women Living With HIV in South Africa: A Mathematical Modeling Study. J Acquir Immune Defic Syndr. 2018 10 01; 79(2):195-205.
Score: 0.134
-
Schnippel K, Firnhaber C, Page-Shipp L, Sinanovic E. Impact of adverse drug reactions on the incremental cost-effectiveness of bedaquiline for drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2018 08 01; 22(8):918-925.
Score: 0.033
-
Schnippel K, Firnhaber C, Berhanu R, Page-Shipp L, Sinanovic E. Direct costs of managing adverse drug reactions during rifampicin-resistant tuberculosis treatment in South Africa. Int J Tuberc Lung Dis. 2018 04 01; 22(4):393-398.
Score: 0.032
-
Schnippel K, Firnhaber C, Conradie F, Ndjeka N, Sinanovic E. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis. Appl Health Econ Health Policy. 2018 Feb; 16(1):43-54.
Score: 0.032
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|